BRCA1 and Familial prostate cancer: There was no difference in OS between patients with advanced prostate cancer and PVs in HRR genes compared to patients without PVs in those genes (HR 0.72; 95% CI: 0.41–1.26; p = 0.251) or in patients with BRCA1/2 and ATM mutations compared to the rest of the patients (HR 0.73; 95% CI: 0.40–1.31; p = 0.284) (Figure 3A and Figure 3B, respectively).